Traws Pharma, Inc. 8-K

What Happened
Traws Pharma, Inc. (TRAW) filed a Form 8-K on June 22, 2026 (Item 7.01, Regulation FD Disclosure) and issued a press release announcing it intends to resubmit an updated data package to the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) to support planned testing of its antiviral candidate, tivoxavir marboxil. The press release is attached to the filing as Exhibit 99.1.

Key Details

• Date filed/announced: June 22, 2026.
• Action: Intends to resubmit an updated data package to the UK MHRA.
• Program: Planned testing (regulatory/clinical engagement) for tivoxavir marboxil.
• Disclosure type: Regulation FD Disclosure included in Form 8-K; press release filed as Exhibit 99.1.

Why It Matters
This filing signals that Traws Pharma is actively pursuing regulatory engagement in the UK for its tivoxavir marboxil program, a necessary step before formal testing can proceed there. For investors, the resubmission and any subsequent MHRA response will be material to the program’s development timeline and potential value creation; monitor future updates for MHRA feedback, submission acceptance, or announced trial start dates.